Pain

The authors of a research letter say a small minority of patients with diabetes have facial pain that cannot otherwise be easily explained.

The injection bags will be available in 1000 mg in 100 mL doses, as well as in 500 mg in 50 mL doses.

Only Nebraska and Vermont saw a decrease in NAS rates between 2010-2017.

The current literature points to the potential efficacy and safety of the anti-depressant drug, but more research is needed to verify its role in managing pain caused by vaso-occlusive crises.

Dr. Rakesh Jetly is leading a new phase 2 study testing psychedelics in veterans with PTSD.

Adolescent delinquency and perceived classmate drug use were linked to adolescent opioid misuse.

In nearly 1.9 million doses of the COVID-19 vaccine there has been only 21 total cases of anaphylaxis.

The 5 companies issued letters will have 15 days to submit a compliance plan.

Dr. Tobias Moeller-Bertram discusses how alternative therapies could replace opioids in the future for chronic pain.

An interview with a pain specialist on advancing alternative pain therapy options.

Adamis plans to address agency concerns regarding the naloxone injection application.

There was a substantial increase in drug use-related endogenous endophthalmitis hospitalizations between 2003 and 2016.

A new study finds patients with sickle cell disease are moderately adherent to hydroxyurea.

NASH and NAFLD are notoriously difficult to treat conditions.

Paul Christo, MD, discusses opioid addiction during the pandemic, the role of the clinician, and offers a hopeful outlook for the future.

An expert discusses steps the FDA can take to strengthen and make more airtight their process for approving new opioids.

An expert discusses the effect the pandemic has had on opioid use and related deaths.

Dr. Moon says new strategies must be implemented to help NAFLD patients deal with pain.

Higher levels of acetaminophen detected in meconium was linked to increased odds of developing ADHD by 6-7 years old.

A pharmacoepidemiologist offers his comments on the ongoing opioid epidemic.

A new cross-sectional study uncovers shortcomings in pivotal trials supporting new drug applications for opioid analgesics, which range from study design to duration.

As part of the TARGET-NASH study, researchers find 18% of NAFLD patients are prescribed opioids because of pain.

About 2/3 of children with asthma had been exposed to opioids prior to birth, according to a new retrospective study.

Findings indicate placebo responses are more than a psychological placebo effect.

Leveraging telemedicine during COVID-19.

An expert explains resources for pain related to rheumatic conditions.

A post-hoc analysis of 3 randomized controlled trials reports on the associations between the IL-6 inhibitor and unacceptable or refractory pain.

Alternate therapies can be more effective than opioids.

Facets of managing pain for rheumatology patients.

The new drug allows for flexible dosing so as to address individual patient needs.